Selective evaluation of a new topical steroid (betamethasone benzoate).
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D001623:Betamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy / Q000473:pathology
D000893:Anti-Inflammatory Agents; D001565:Benzoates; D005938:Glucocorticoids; D010919:Placebos; D001623:Betamethasone